The Food and Drug Administration (FDA) has announced a nationwide recall of over 580,000 bottles of prazosin hydrochloride, a blood pressure medication, due to potential contamination with a cancer-causing chemical. The drug, also prescribed for sleep disturbances linked to post-traumatic stress disorder (PTSD), was voluntarily recalled by New Jersey-based Teva Pharmaceuticals USA and distributor Amerisource Health Services.
The affected capsules, available in 1 mg, 2 mg, and 5 mg doses, were classified as a Class II risk by the FDA. The agency warned that certain batches may contain nitrosamine impurities, which can form during manufacturing or storage and are considered potentially carcinogenic. Patients relying on prazosin for blood pressure management or PTSD-related conditions now face uncertainty about their medication’s safety.
Teva Pharmaceuticals has not yet provided a statement regarding the recall. The incident highlights ongoing concerns about pharmaceutical supply chain integrity and the need for rigorous oversight in drug production and storage.
